Call Start: 08:00 January 1, 0000 8:58 AM ET
Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Q2 2022 Earnings Conference Call
August 9, 2022 08:00 ET
Company Participants
Mark Jacobson - Chief Operating Officer
Herriot Tabuteau - Founder, Chairman, Chief Executive Officer & President
Lori Englebert - Executive Vice President of Commercial & Business Development
Nick Pizzie - Chief Financial Officer
Conference Call Participants
Charles Duncan - Cantor Fitzgerald
Yatin Suneja - Guggenheim Partners
Jason Gerberry - Bank of America
Joseph Thome - Cowen
Graig Suvannavejh - Mizuho Securities
Chris Howerton - Jefferies
Matt Kaplan - Ladenburg Thalmann
Myles Minter - William Blair
David Hoang - SMBC
Operator
Good morning and welcome to the Axsome Therapeutics Conference Call. I would now like to turn the conference over to your host, Mark Jacobson, Chief Operating Officer at Axsome Therapeutics. Mark, please go ahead.
Mark Jacobson
Thank you, operator. Good morning and thank you all for joining us on today's conference call. This morning, we issued our earnings press release, providing a corporate update and details of the company's financial results for the second quarter of 2022. And the release crossed the wire a short time ago and is available on our website at axsome.com.
During today's call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our investigational agents; our clinical and non-clinical plans; our plans to present or report additional data; the anticipated conduct and the source of future clinical trials; regulatory plans; future research and development plans; commercial plans; and possible intended use of cash and investments. These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the Securities and Exchange Commission, including our quarterly and annual reports. You are cautioned not to place undue reliance on these forward-looking statements which are only made as of today’s date and the company disclaims any obligation to update such statements.
Joining me on the call today are Dr. Herriot Tabuteau, Chief Executive Officer; Nick Pizzie, Chief Financial Officer; and Lori Englebert, Senior Vice President of Commercial and Business Development. Herriot will first provide an overview of the company and then review recent developments and upcoming milestones. Following Herriot, Lori will provide a commercial update and then Nick will review our financial results. We will then open the line for questions. Questions will be taken in the order they are received.